Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4238409 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3SIGMAR1KCNH2 | |
| SCHEMBL3244911 | 0.84 | SLC6A2 (0.77) | SLC6A2SLC6A4SLC6A3SIGMAR1KCNH2 | |
| SCHEMBL20766385 | 0.82 | SIGMAR1 (0.73) | SLC6A2SLC6A4SLC6A3SIGMAR1KCNH2 | |
| SCHEMBL2301711 | 0.82 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3KCNH2HTR3A | |
| SCHEMBL25727760 | 0.79 | SIGMAR1 (0.64) | SLC6A2SLC6A4SLC6A3SIGMAR1KCNH2 | |
| SCHEMBL25379677 | 0.79 | SLC6A4 (0.44) | SLC6A2SLC6A4SLC6A3SIGMAR1KCNH2 | |
| SCHEMBL21618371 | 0.79 | TDP1 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2HTR3A | |
| SCHEMBL2298790 | 0.79 | LTA4H (0.46) | SLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL2296643 | 0.79 | TDP1 (0.67) | SLC6A2SLC6A4SLC6A3KDM1AKMT2A | |
| SCHEMBL15301000 | 0.79 | TDP1 (0.45) | SLC6A2SLC6A4SLC6A3KCNH2HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2017-02-09 | — | — | US | disclosed |
| US-9415037-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2016-08-16 | — | — | US | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2015-06-04 | — | — | US | disclosed |
| CN-102105471-B | Novel compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS N.V. (BE) | 2014-10-15 | — | — | CN | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-2361251-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2011-08-04 | — | — | US | disclosed |
| CN-102105471-A | Novel compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV | 2011-06-22 | — | — | CN | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150856-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | SLC6A2 4604/4885SLC6A4 4238/4885SLC6A3 4617/4885 |
| US-10206907-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | TRAF6, TLR6, IL6 | SLC6A2 4545/4885SLC6A4 4257/4885SLC6A3 4624/4885 |
| US-20170035738-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TLR6, TRAF6, BMP6 | SLC6A2 4604/4885SLC6A4 4238/4885SLC6A3 4617/4885 |
| US-20110190260-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | TRAF6, IL6, TLR6 | SLC6A2 4632/4885SLC6A4 4381/4885SLC6A3 4653/4885 |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | SLC6A2 475/4885SLC6A4 502/4885SLC6A3 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.